Peptide preparation derived from porcine brain tissue; approved in ~50 countries for stroke and dementia, not FDA approved.
Mixture of low-molecular-weight peptides (<10 kDa) produced by standardized enzymatic breakdown of purified brain proteins. Proposed neurotrophic and neuroprotective effects.
Multiple RCTs for ischemic stroke, traumatic brain injury, vascular dementia, and Alzheimer disease. Cochrane reviews note methodological concerns.
No FDA label or editorial side-effect profile is on file for this compound yet. See the clinical trials and citations sections for study-reported safety data.
No documented drug interactions on file.
Not FDA approved. Approved in ~50 countries including most of Europe, Russia, and China.
Not available via 503A/503B compounding pharmacies.
Regulatory data last verified 4/19/2026
Showing 12 of 25 indexed studies. View all on ClinicalTrials.gov →
Showing 20 of 30 papers. View all on PubMed →